Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2013, Article ID 583051, 5 pages
Clinical Study

Characteristics and Results of the Treatment of Multiple Myeloma in the Subject under the Age of 65 at the University Hospital of Yopougon in Abidjan, Côte d’Ivoire

Department of Clinical Hematology, Yopougon Teaching Hospital, P.O. Box 632, Abidjan 21, Cote d’Ivoire

Received 30 October 2013; Revised 7 December 2013; Accepted 8 December 2013

Academic Editor: Aldo Roccaro

Copyright © 2013 Diebkilé Aïssata Tolo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. B. Chaubert, F. Delacretaz, and P. M. Schmidt, “Myélome multiple,” Schweizerische Medical Forum, vol. 5, pp. 309–316, 2005. View at Google Scholar
  2. R. Bataille, “Myélome multiple: traitements symptomatiques et antitumoraux,” in Encycl Méd Chir, Hématologie, p. 17, Elsevier, Paris, France, 1996. View at Google Scholar
  3. J.-L. Harousseau and M. Dreyling, “Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, no. 5, pp. v155–v157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. W. J.- Dong, M. Chang-Ki, and H. Kyungja, “Impact of genetic abnormalities on the prognoses and clinical parameters of patients with multiple myeloma,” Annals of Laboratory Medicine, vol. 33, no. 4, pp. 248–254, 2013. View at Google Scholar
  5. D. E. Reece, “Recent trends in the management of newly diagnosed multiple myeloma,” Current Opinion in Hematology, vol. 16, no. 4, pp. 306–312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Palumbo and C. Cerrato, “Diagnosis and therapy of multiple myeloma,” The Korean Journal of Internal Medicine, vol. 28, no. 3, pp. 263–273, 2013. View at Google Scholar
  7. J. M. Bird, R. G. Owen, S. D'Sa et al., “Guidelines for the diagnosis and management of multiple myeloma 2011,” British Journal of Haematology, vol. 154, no. 1, pp. 32–75, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Oranger, C. Carbone, and M. Grano, “Cellular mechanisms of multiple myeloma bone disease,” Clinical and Developmental Immunology, vol. 2013, Article ID 289458, 14 pages, 2013. View at Publisher · View at Google Scholar
  9. A. Dispenzieri and R. A. Kyle, “Multiple myeloma: clinical features and indications for therapy,” Best Practice and Research, vol. 18, no. 4, pp. 553–568, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. R. A. Kyle, M. A. Gertz, T. E. Witzig et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” Mayo Clinic Proceedings, vol. 78, no. 1, pp. 21–33, 2003. View at Google Scholar · View at Scopus
  11. G. R. Shaw, “Nonsecretory plasma cell myeloma—becoming even more rare with serum free light-chain assay: a brief review,” Archives of Pathology and Laboratory Medicine, vol. 130, no. 8, pp. 1212–1215, 2006. View at Google Scholar · View at Scopus
  12. D. Pulte, M. T. Redaniel, H. Brenner, L. Jansen, and M. Jeffreys, “Recent improvement in survival of patients with multiple myeloma: variation by ethnicity,” Leukemia Lymphoma. In press.
  13. R. Alexanian, B. Barlogie, and S. Tucker, “VAD-based regimens as primary treatment for multiple myeloma,” American Journal of Hematology, vol. 33, no. 2, pp. 86–89, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Wan, “Therapeutic efficacy analysis of VD regimen and VAD regimen for multiple myeloma,” Zhongguo Shi Yan Xue Ye Xue Za Zhi, vol. 21, no. 3, pp. 647–649, 2013. View at Google Scholar